Answers are grounded in this paper and cite their sources.
Human topoisomerase IIα (TOP2A) is frequently overexpressed in aggressive cancers, making it an attractive therapeutic target. Herein, we employed an integrated in silico and experimental approach to identify novel TOP2A inhibitors. A library of 669,069 filtered, drug-like bioactive small molecules from PubChem was screened against human TOP2A (PDB ID: 5GWK) using Schrödinger Maestro with Glide SP and XP docking, yielding 202 compounds with docking scores superior to etoposide. Subsequent filtering for PAINS, ADMET, and selectivity assessment against other human type I and type II topoisomerases yielded 21 ligands. Docking against multidomain TOP2A (PDB ID: 6ZY8) revealed preferential binding at the DNA-gate over the ATP-binding N-gate region, with L8 (pitavastatin) achieving the highest docking score. Based on their docking score, selectivity, and commercial availability, five ligands were selected for experimental evaluation. A cell viability assay showed that pitavastatin and L21 (PubChem CID: 7369491) exhibited potent cytotoxicity against MDA-MB-231 and MCF-7 breast cancer cells, respectively, with reduced toxicity against normal HEK293 cells. Both ligands induced S-phase arrest and late apoptosis in MDA-MB-231 cells, with pitavastatin outperforming etoposide. The in vitro plasmid relaxation assay confirmed that all five ligands inhibited TOP2A activity consistent with the poison mechanism, while pitavastatin exhibited a nonintercalative mode of binding to DNA. Molecular dynamics simulations for pitavastatin supported stable binding within the TOP2A active site. These findings identify pitavastatin as a promising repurposed candidate for TOP2A-targeted therapy, particularly against the triple-negative breast cancer cell line MDA-MB-231.
No takes yet. Share an insight, caveat, or question.
Sebastian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: